Is Hormone Therapy + Everolimus Effective for Breast Cancer?
Is Hormone Therapy + Everolimus Effective for Breast Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Is Hormone Therapy + Everolimus Effective for Breast Cancer?
On May 23, 2022, Thomas Bachelot and colleagues from Centre Leon Berard published the results of a Phase III clinical trial (NCT01805271) on the efficacy and safety of hormone therapy + Everolimus as adjuvant therapy in high-risk, hormone receptor-positive, HER2-negative primary breast cancer patients in the Journal of Clinical Oncology.
This Phase III clinical trial randomized high-risk, hormone receptor-positive, HER2-negative primary breast cancer patients (N = 1278) into two groups: hormone therapy + Everolimus (continued for 2 years) and hormone therapy + placebo (continued for 2 years). The primary endpoint was progression-free survival.
The trial results showed that for the primary endpoint, the 3-year progression-free survival rate was: hormone therapy + Everolimus group 88% versus hormone therapy + placebo group 89%, showing no significant difference between the two groups. Regarding safety, the incidence of Grade 3 or higher adverse events was: hormone therapy + Everolimus group 29.9% versus hormone therapy + placebo group 15.9%. The rate of treatment discontinuation early in the trial was: hormone therapy + Everolimus group 53.4% versus hormone therapy + placebo group 22.3%.
Based on the Phase III clinical trial results, Thomas Bachelot and colleagues concluded that high-risk, hormone receptor-positive, HER2-negative primary breast cancer patients receiving hormone therapy + Everolimus as adjuvant therapy showed no significant improvement in progression-free survival, and approximately half of patients discontinued Everolimus treatment. They do not recommend Everolimus as adjuvant therapy.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.02179
https://ascopubs.org/doi/abs/10.1200/JCO.21.02179
This website uses cookies to understand how you interact with it. By accepting, you agree to our use of cookies. Privacy Policy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4